EMYRIA LIMITED — Capital/Financing Update 2020

Nov 5, 2020

ASX/Media Release

==> picture [116 x 62] intentionally omitted <==

06/11/2020

RELEASE OF UNLISTED OPTIONS FROM ESCROW

Emyria Limited (ASX: EMD) (Emyria or the Company), a company that develops and commercialises clinical technologies and data products, and also manages an Australia-wide clinical service for patients with unmet medical needs (Emerald Clinics), advises that 1,000,000 unlisted options exercisable at $0.45 on or before 13 June 2023 will be released from escrow on 11 November 2020. In addition, 6,250,000 unlisted options exercisable at $0.45 on or before 13 June 2023 and 600,000 unlisted options exercisable at $0.45 on or before 26 September 2023, escrowed for various periods at listing, have also been released from escrow.

Following the release of these options from escrow the balance of 10,500,000 unlisted options exercisable at $0.45 on or before 13 June 2023 on issue remain in escrow until 24 Months from Official Quotation of the Company's shares on ASX.

Release authorised by: Simon Robertson Company Secretary

For further information

Dr Michael Winlo Jane Morgan CEO Media/Investor Relations (08) 6559 2800 + 61 (0) 405 555 618 mwinlo@emyria.com jm@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited creates unique data products that accelerate the development of new treatments for patients with unmet needs. Emyria achieves this by analysing the deep, deidentified clinical data gathered from its specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria’s data products accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into the safety, quality and efficacy of those unapproved treatments, in real patients in the community. Emyria’s data assets are also a source of unique IP for Emyria, which along with its remote patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets and insights as well as the care provided to patients.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.